What is cemiplimab?

Cemiplimab (Cemiplimab) is an immunotherapy drug that belongs to the class of anti-cancer immune checkpoint inhibitors. Its mechanism of action is designed to enhance the immune system's ability to attack certain types of cancer cells, thereby improving patient outcomes.

The drug's primary use is to treat advanced squamous non-small cell lung cancer (SCC) with highPD-L1 (programmed death ligand-1) expression. PD-L1 is a protein that is usually highly expressed on certain cancer cells. It interacts with the PD-1 receptor in the immune system, inhibiting the immune response, thereby helping cancer cells evade attack by the immune system.

The mechanism of action of cimipilimab blocks the interaction between PD-1 and PD-L1, allowing T cells to recognize and attack cancer cells more effectively, helping to reverse immune evasion. This treatment has the potential to extend patient survival and improve quality of life.

However, cimepilimab may cause some adverse reactions, such as fatigue, rash, nausea, diarrhea, etc., as well as immune-related adverse events, such as immune thyroid disease. Therefore, patients should fully discuss the potential risks and benefits with their doctor before undergoing treatment.

Overall, cimepilimab represents an important innovation in cancer treatment, providing a new treatment option that promises to improve their survival prospects and quality of life, especially for patients who are refractory to traditional treatments. Patients should receive treatment under physician advice and supervision to ensure its safe and effective use.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.